[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-bacterial-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-bacterial-infections":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601538","identification-of-clinical-genetic-and-immunological-factors-involved-in-the-development-of-severe-bacterial-infections-in-pediatrics-100601538",false,"NCT07111793","Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics","IBSoFACTo : Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics","IBSoFACTo","Inclusion Criteria:\n\nFor patients:\n\n* Patient included in the DIABACT IV study between 2015 and 2018, following hospitalization in a pediatric intensive care unit in France for a severe bacterial infection.\n* Patient affiliated to a social security system\n* Patient alive at the time of inclusion.\n* Written consent from legal representatives for participation in research. If one of the legal representatives is unable to complete\u002Fsign the written consent, it will be sought orally by telephone and recorded in the patient's file. If the patient is over 18, written consent will be obtained. If the patient is a minor, consent will be sought with communication adapted to his\u002Fher level of understanding and age.\n\nFor parents:\n\n* Patient's biological parents\n* Written consent\n\nExclusion Criteria:\n\n* Persons under court protection\n* Refusal to participate in research","ALL",{"count":19,"type":20},1401,"ESTIMATED","INTERVENTIONAL",[23],"NA","Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics.\n\nThe study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS.\n\nIn parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.",[26],"Severe Bacterial Infections",[28,29,30,31],"Severe bacterial infections","Whole-exome sequencing","Inborn errors of immunity","pediatrics","RECRUITING","2026-10-08",{"date":35,"type":36},"2026-10-13","ACTUAL",{"date":38,"type":36},"2026-03-18",{"date":40,"type":20},"2029-12-18",{"name":42,"class":43},"Nantes University Hospital","OTHER",7,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100605823","evaluation-of-the-dialytic-clearance-of-the-combination-of-peracillin-and-tazobactam-100605823","NCT07167524","Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam","Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam in Patients Receiving Continuous Renal Replacement Therapy in Intensive Care","EPIC","Inclusion Criteria:\n\n* Adult patient over 18 years of age;\n* Patient admitted to intensive care with a prescription for cREV (CVVH (pre- or post-dilution (convection)), CVVHD (diffusion), CVVHDF);\n* Diagnosed or suspected infection sensitive to the piperacillin-tazobactam combination administered by continuous infusion as part of the patient's standard care;\n* Concomitant prescription of piperacillin-tazobactam and cREV;\n* Patient affiliated with a social security scheme;\n* Adult who has read and understood the information letter and has not expressed non-opposition. Due to the potential life-threatening emergency, if the patient is unable to express their non-opposition, the consent of a trusted person or, where applicable, relatives will be sought.\n\nExclusion Criteria:\n\n* Documented or suspected allergy to penicillins;\n* Opposition from the patient or trusted person;\n* Pregnant, childbirth, or breastfeeding woman;\n* Minor patient;\n* Person deprived of liberty by an administrative or judicial decision;\n* Person placed under judicial protection, guardianship, or curatorship.","18 Years",{"count":55,"type":20},24,"OBSERVATIONAL","Severe bacterial infections, often responsible for sepsis and septic shock, are a major challenge in critical care: approximately 50% of patients are affected, with a mortality rate of up to 40%. Their initial management consists of antibiotic therapy with an adapted spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumopathies, intra-abdominal infections, urinary tract infections, etc.). Mortality rates of up to 40%. Their initial management consists of antibiotic therapy with an appropriate spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumonia, intra-abdominal infections, urinary tract infections, etc.).\n\nIntensive care patients with septic shock exhibit specific pharmacokinetics with an increased volume of distribution, notably due to significant capillary leakage, often disrupted hepatic metabolism, possible hypoalbuminemia, the presence of renal hyperclearance in the initial phase or conversely, the onset of renal failure with altered glomerular filtration rate, sometimes leading to extrarenal clearance, changes that have consequences for the efficacy and toxicity of the administered antibiotic therapy. Sepsis itself also causes renal dysfunction, with the main pathophysiological hypotheses being an alteration of microcirculation, cellular metabolic reprogramming, and deregulation of the inflammatory response. It is therefore essential to focus on the dosages administered and the pharmacokinetics of these patients. Indeed, underdosing is associated with the emergence of resistance and a poorer prognosis in intensive care patients: increased risk of treatment failure, length of stay and mortality. Conversely, significant overdoses can be associated with a poorer renal prognosis, seizures, encephalopathy which can lead to delayed awakening, prolonged duration of mechanical ventilation and intensive care stay.",[59,26],"Sepsis",[61,62,63],"medical resuscitation","antibiotic therapy","clearance of piperacillin and tazobactam","NOT_YET_RECRUITING","2025-09-03",{"date":67,"type":36},"2025-09-11",{"date":69,"type":20},"2025-10-01",{"date":71,"type":20},"2028-04-01",{"name":73,"class":43},"University Hospital, Rouen",1]